Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying how the substance gadoquatrane behaves in the body and its safety in children who need a special type of scan called a contrast-enhanced magnetic resonance imaging (MRI). The study involves children from birth up to 18 years old who require this scan for various medical reasons. Gadoquatrane is given as a solution for injection, and it helps to improve the quality of the MRI images by enhancing the contrast.

The purpose of the study is to understand how gadoquatrane moves into, through, and out of the body after a single injection. The study will observe how the body processes this substance and will monitor any side effects that may occur. The children participating in the study will receive a single dose of gadoquatrane through an intravenous injection, which means it is injected directly into a vein.

Throughout the study, researchers will collect information on how gadoquatrane is distributed in the body and how quickly it is cleared. They will also keep track of any side effects that might happen within a week after the injection. This information will help determine the safety and effectiveness of gadoquatrane in improving MRI scans for children.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participants from birth to less than 18 years of age are eligible to join the study. A legal guardian must provide signed informed consent.

    Participants must have a clinical reason to undergo a contrast-enhanced magnetic resonance imaging (CE-MRI) and be able to follow study procedures.

  2. Step 2

    Preparation for the procedure

    Before the procedure, female participants may need to undergo pregnancy testing, depending on age and local regulations.

    A legal guardian should accompany the participant to the study site on each assessment day.

  3. Step 3

    Administration of the medication

    The medication used in the study is called BAY 1747846, which contains the active substance gadoquatrane.

    Gadoquatrane is administered as a solution for injection through an intravenous route.

    The dosage is a single injection of 0.04 mmol of gadoquatrane per kilogram of body weight.

  4. Step 4

    Undergoing the CE-MRI

    After the injection, the participant will undergo a contrast-enhanced magnetic resonance imaging (CE-MRI) to assess how the medication moves through the body.

  5. Step 5

    Monitoring and follow-up

    Participants will be monitored for any treatment-emergent adverse events (TEAEs) within 24 hours after the injection.

    A follow-up period of 7 days is required to observe any additional effects or reactions.

Who can join the trial?

6 criteria

  • Participants must be from birth to under 18 years old at the time of signing the informed consent form.
  • Participants need to have a medical reason to undergo a **CE-MRI** (a special type of scan that uses a contrast agent to get clearer images) for any health condition in any part of the body and must be able to go through the study procedures as judged by the doctor in charge.
  • Participants can be either male or female.
  • For female participants, appropriate birth control and pregnancy testing are required based on their age and level of sexual activity, following local rules.
  • The legal guardian(s) must be able to provide signed informed consent, agreeing to follow the study's requirements and restrictions.
  • If required by law, a legal guardian must be available to assist the study staff, accompany the participant to the study site on each assessment day, and consistently provide information about the participant during scheduled study visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Gadoquatrane is a contrast agent used in magnetic resonance imaging (MRI) to help create clearer images of the body's internal structures. In this clinical trial, it is being studied to understand how it behaves in the body (pharmacokinetics) and to ensure its safety when used in children from birth to under 18 years old. The medication is given as a single intravenous injection before the MRI scan.

What is already known about the treatment

Gadoquatrane – Gadoquatrane is administered as an intravenous injection and is used to enhance contrast in magnetic resonance imaging (MRI) for children. It is currently being studied in clinical trials to assess its pharmacokinetics and safety in pediatric patients. The main therapeutic indication is to improve the clarity of MRI images, which helps in better diagnosis. At the molecular level, gadoquatrane works by altering the magnetic properties of nearby water molecules, enhancing the contrast of the images. It is classified as a gadolinium-based contrast agent in pharmacology.

Investigated diseases

Contrast Enhancement in Magnetic Resonance Imaging in Children – This is not a disease but a medical procedure used to improve the clarity of MRI images in pediatric patients. It involves the use of contrast agents, which are substances injected into the body to highlight specific areas during imaging. The contrast agent helps to differentiate between normal and abnormal tissues, making it easier to identify issues such as tumors, inflammation, or blood vessel abnormalities. The process is particularly useful in detecting and assessing conditions affecting the brain, spine, and other organs. The enhancement effect is temporary, as the contrast agent is eventually cleared from the body. This procedure is commonly used in clinical settings to aid in the diagnosis and monitoring of various medical conditions in children.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2022-501883-17-00Protocol code21196Estimated enrolment143 patientsSponsorBayer AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).